![[CME 2] Guide to Understanding & Managing Schizophrenia](https://psychiatryeducationforum.com/wp-content/uploads/2020/11/Untitled-design-2.png)
CME ACADEMY #2
GUIDE TO UNDERSTANDING & MANAGING SCHIZOPHRENIA
TOTAL CREDITS: 7.75 AMA PRA CATEGORY 1 CREDITS
ENROLLEMENT CLOSED
CME EXPIRING ON:Sep 28, 2025
LEARNING OBJECTIVES:
By the end of this course, participants should be able to:
- Compare and evaluate the efficacy, dosing, and side effects of 32 antipsychotics in the treatment of acute multi-episode schizophrenia.
- Implement evidence-based strategies for the management of clozapine-resistant schizophrenia and develop protocols for managing missed doses of clozapine.
- Assess and mitigate the risks associated with antipsychotic use, particularly the risk of pneumonia.
- Differentiate the effectiveness of various antipsychotic formulations, including Aripiprazole versus Brexpiprazole and topical versus sublingual Asenapine.
- Integrate psychological interventions for treating auditory hallucinations alongside pharmacological therapies.
- Understand the impact of schizophrenia’s progression with age on long-term management strategies.
- Recognize the implications of adolescent cannabis use on the risk of developing schizophrenia.
- Stay updated on the latest research regarding the glutamatergic synapse in schizophrenia.
Course Instructor
TABLE OF CONTENT:
Comprehensive Review of Antipsychotic Medications
Special Considerations in Antipsychotic Treatment
Understanding Schizophrenia Progression & Psychological Approaches
Emerging Research and Risk Factors
Earn CME Certificate
Accreditation and Designation Statements and Disclosure Report:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the Psychiatry Education Forum.
PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of 7.75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- Enduring activity date: September 28, 2024 – September 28, 2025
Financial Disclosures:
- All presenters, planners, editors, or staff report no relationships to disclose: “I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”
